Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting mGlyR with nanobodies for depression.

Nature communications·2026

Same author

Engineered antibodies that stabilize drug-modified KRAS<sup>G12C</sup> neoantigens enable selective and potent cross-HLA immunotherapy.

Nature communications·2025

Same author

Generation of Antibody Libraries for Phage Display: Preparation of Electrocompetent <i>E. coli</i>.

Cold Spring Harbor protocols·2024

Same author

Generation of Antibody Libraries for Phage Display: Library Reamplification.

Cold Spring Harbor protocols·2024

Same author

Phage Display Selection of Antibody Libraries: Screening of Selected Binders.

Cold Spring Harbor protocols·2024

Same author

Generation and Selection of Phage Display Antibody Libraries in Fab Format.

Cold Spring Harbor protocols·2024

Search research articles

Related Experiment Video

Updated: Nov 6, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Antibody-based cancer therapy.

Rebecca S Goydel¹, Christoph Rader²

¹Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.

|May 5, 2021

Summary

Antibody therapeutics, with nearly 100 Food and Drug Administration approvals, are vital in oncology. This review explores antibody-based cancer therapies, categorized by their mechanisms, and their evolving landscape.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Experiment Videos

Last Updated: Nov 6, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Area of Science:

Biotechnology
Immunology
Oncology

Background:

Antibody therapeutics have become major pharmaceuticals over 25 years.
Nearly 100 Food and Drug Administration approvals and $100 billion in global sales highlight their success.
Approximately 50% of antibody therapeutics are utilized in cancer treatment.

Purpose of the Study:

To provide an overview of antibody-based cancer therapies.
To discuss the mechanisms of action for antibody-based cancer therapies.
To offer an outlook on the future of antibody-based cancer therapy.

Main Methods:

Review of existing literature on antibody therapeutics in oncology.
Categorization of antibody-based cancer therapies based on mechanisms of action.
Analysis of the structural properties of antibody molecules.

Main Results:

Antibody-based cancer therapies are categorized into three main types: natural properties, T-cell engagement, and payload delivery.
The efficacy of these therapies is based on the stable and modular architecture of antibodies.
The field of antibody-based cancer therapy is rapidly evolving.

Conclusions:

Antibody therapeutics represent a significant advancement in cancer treatment.
The diverse mechanisms of action offer various therapeutic strategies.
The modular nature of antibodies supports ongoing innovation and future development in oncology.